Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress

Collegium Pharmaceutical reported Q2 net revenues of $199.9M, up 6% YoY, driven by JORNAY PM revenue of $46.1M (+41% YoY) while AZSTARYS contributed $12.9M as a partial-quarter acquisition. Pain portfolio net revenues fell 9% YoY to $140.9M, with Nucynta franchise down 24% YoY. The company completed the AZSTARYS acquisition and reiterated full-year 2026 guidance for JORNAY PM, while raising AZSTARYS revenue/net guidance (AZSTARYS revenue, net to $65–$75M vs prior $60–$70M) and updating Product Revenues, Net to $825–$855M and Adjusted EBITDA to $445–$470M (down vs prior range due to lower net pricing on Nucynta AG versions).

Analysis

The incremental positive is not the quarter itself; it is the portfolio transition. COLL is starting to look less like a fading pain royalty stream and more like a self-funded specialty commercial platform, which should support a higher durability multiple if ADHD can compound through the school-year prescribing window. The market will likely key on whether the new asset is additive or merely offsets the structural slide in the legacy cash engine; that distinction matters because the equity is now more exposed to execution than to pure patent-duration optics.

Near term, the biggest mechanical support is seasonal: provider engagement and refill cadence typically matter most over the next 6-10 weeks, so any surprise in script acceleration should show up quickly in the stock. The risk is that the revenue bridge still relies on aggressive selling efficiency while the pain franchise continues to shrink; if the commercial leverage does not improve, operating margins can compress even with top-line growth because the acquired asset comes with amortization, integration expense, and higher balance-sheet complexity.

Contrarian view: consensus may be underestimating how much of the “growth” is really a mix shift from mature cash flows into a more competitive ADHD category, where share gains can be fickle and promo intensity can rise. The stock is probably not pricing a clean step-change in quality until management proves that AZSTARYS plus JORNAY can sustain growth without another SG&A leg-up. Falsifier: if ADHD revenue growth decelerates in the next 1-2 quarters or if 2H guidance is cut again due to pricing/volume pressure in the legacy pain line, the multiple re-rating thesis should be deferred.

Key Decisions for Investors

• Tactically long COLL into the back-to-school catalyst window (next 4-8 weeks) if shares retrace on the headline print; target is a rerating on evidence of prescription momentum rather than on GAAP earnings. Risk/reward is attractive only if the market believes the new ADHD platform can offset pain erosion; cut if management signals weaker September trends.
• Pair trade: long COLL / short XBI for 1-3 months to isolate execution alpha from broad biotech beta. This works if investors start rewarding cash-generative specialty commercialization over unprofitable platform names; unwind if COLL loses ADHD traction or if the sector re-rates on macro/MLR sentiment.
• Buy a modest call spread on COLL expiring after the next quarterly update only if you want defined risk around integration. The trade needs continued script acceleration and no further guidance deterioration; the thesis breaks if revenue quality worsens or if adjusted EBITDA is again revised lower.
• Do not chase the stock on the press release; wait for the call and channel checks on AZSTARYS conversion. Missing data: whether the added salesforce is producing net-new prescriber share or just lifting first-fill traffic. If adoption is broad but shallow, the upside is likely capped.
• Watch for a short opportunity on any strength above the revised 2026 EBITDA multiple if the market over-discounts the acquisition synergy story. The bear case is that leverage to the pain franchise disappears faster than ADHD scales, leaving the equity as a lower-quality growth story with more leverage, not less.